Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2023 | The potential of combination therapy in migraine

Alan Rapoport, MD, University of California, Los Angeles, CA, discusses the practice of combining preventive and acute care drugs for the treatment of migraines. While preventive drugs may not always completely prevent every migraine attack, patients can still take an acute care drug to alleviate their symptoms. Prof. Rapoport mentions two specific options: a monoclonal antibody against CGRP or its receptor for prevention and a gepant for acute relief. Although the safety of this practice hasn’t been extensively studied, many healthcare professionals are already implementing it, and it appears to be safe. By combining these drugs, doctors can provide a more comprehensive and tailored approach to migraine management. This interview took place at the European Academy of Neurology (EAN) 2023 Congress in Budapest, Hungary.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Alan Rapoport reports the following disclosures: I have worked with all four of the monoclonal antibodies companies and both of the gepant companies.